J Hepatol: Prevalence of liver fibrosis/cirrhosis in patients with T2DM

In a prospective cohort that systematically evaluated cirrhosis due to advanced fibrosis or nonalcoholic fatty liver disease (NAFLD), data on patients with type 2 diabetes mellitus (T2DM) were limited
.
The study was designed to assess the prevalence of liver fibrosis and cirrhosis in people with type 2 diabetes
.

The study prospectively recruited ≥ 50-year-old patients with T2DM
.
Patients received standardized clinical study visits
for magnetic resonance imaging proton density-fat fraction (MRI-PDFF), magnetic resonance elastography (MRE), vibration-controlled transient elastography (VCTE), and controlled attenuation parameters (CAP).
After excluding other liver diseases, NAFLD is defined as MRI-PDFF≥5
%.
If MRE is not available, advanced fibrosis and cirrhosis are defined by established cirrhosis
cutpoints on the MRE or VCTE.

Of the 524 patients screened, 501 patients with T2DM (63% women) were eligible
for inclusion.
The mean age of the subjects was 64.
6 (±8.
1) years and the average BMI was 31.
4 (±5.
9) kg/m2
.
The incidence of NAFLD, advanced liver fibrosis, and cirrhosis was 65%, 14%, and 6%,
respectively.
In multivariate corrected models, obesity and insulin use were associated with an increased odds ratio for advanced liver fibrosis after adjustment for age and sex (ORs 2.
5 and 2.
71, respectively).

Of the 29 patients with cirrhosis, two were diagnosed with hepatocellular carcinoma and one with gallbladder adenocarcinoma
.

Overall, in the prospective cohort of T2DM patients ≥ 50 years of age, the prevalence of advanced liver fibrosis was 14% and the prevalence of cirrhosis was 6%; Suggestive ≥ 50-year-old T2DM patients are at higher risk
of liver fibrosis/cirrhosis.

Original source:

Ajmera Veeral,Cepin Sandra,Tesfai Kaleb et al.
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
[J] .
J Hepatol, 2022, 10.
1016/j.
jhep.
2022.
11.
010